Our findings reveal that while GCs induce GILZ expression in both glioma lines, PD-L1 downregulation was observed only in U87 cells, suggesting a differential regulatory mechanism that may be relevant for optimizing immunotherapeutic strategies in GBM. The gene discussed is TSC22D3; the disease is glioblastoma.